company background image
HGEN.Q logo

Humanigen OTCPK:HGEN.Q Stock Report

Last Price

US$0.000001

Market Cap

US$119.0

7D

-99.5%

1Y

-100.0%

Updated

15 Jul, 2024

Data

Company Financials

Humanigen, Inc.

OTCPK:HGEN.Q Stock Report

Market Cap: US$119.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

HGEN.Q Stock Overview

A clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. More details

HGEN.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Risk Analysis

Highly volatile share price over the past 3 months

Revenue has declined by 59% over the past year

Does not have a meaningful market cap ($119)

Negative shareholders equity

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Humanigen, Inc. Competitors

ObsEva

OTCPK:OBSE.F

US$1.2k

Mymetics

OTCPK:MYMX

US$151.0

Infinity Pharmaceuticals

OTCPK:INFI.Q

US$90.0

RegeneRx Biopharmaceuticals

OTCPK:RGRX

US$2.1k

Price History & Performance

Summary of share price highs, lows and changes for Humanigen
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.21
52 Week LowUS$0.000001
Beta-1.34
1 Month Change0%
3 Month Change0%
1 Year Change-100.00%
3 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Aug 12

Humanigen plunges 57% as trial for COVID-19 therapy fails

Jul 13

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Jul 06

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

Oct 30
Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Jul 14
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.

Jun 14

Humanigen submits lenzilumab COVID-19 EUA application to FDA

May 28

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

May 05

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

May 05
Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Mar 31
We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Feb 26
Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Jan 29

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Jan 11

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Jan 04
We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Humanigen secures new U.S. patent for lenzilumab

Dec 28

Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme

Dec 17

Humanigen EPS misses by $0.16

Nov 11

Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19

Nov 06

Humanigen executes lenzilumab licensing deal in Asia for COVID-19

Nov 03

Humanigen Dosing Phase 3  Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 01

Dosing underway in lenzilumab late-stage study in COVID-19

Oct 30

Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19

Oct 29

Shareholder Returns

HGEN.QUS BiotechsUS Market
7D-99.5%2.6%2.8%
1Y-100.0%-3.3%24.6%

Return vs Industry: HGEN.Q underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: HGEN.Q underperformed the US Market which returned 22% over the past year.

Price Volatility

Is HGEN.Q's price volatile compared to industry and market?
HGEN.Q volatility
HGEN.Q Average Weekly Movement102,515.4%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market3.1%

Stable Share Price: HGEN.Q's share price has been volatile over the past 3 months.

Volatility Over Time: HGEN.Q's weekly volatility has increased from 50618% to 102515% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20006Cameron Durrantwww.humanigen.com

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis.

Humanigen, Inc. Fundamentals Summary

How do Humanigen's earnings and revenue compare to its market cap?
HGEN.Q fundamental statistics
Market capUS$119.00
Earnings (TTM)-US$53.63m
Revenue (TTM)US$1.70m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is HGEN.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HGEN.Q income statement (TTM)
RevenueUS$1.70m
Cost of RevenueUS$38.73m
Gross Profit-US$37.03m
Other ExpensesUS$16.61m
Earnings-US$53.63m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.45
Gross Margin-2,179.40%
Net Profit Margin-3,156.80%
Debt/Equity Ratio0%

How did HGEN.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/15 20:15
End of Day Share Price 2024/07/15 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Humanigen, Inc. is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Cosme OrdoñezB. Riley Wealth
Olga SmolentsevaBryan Garnier & Co
Louise ChenCantor Fitzgerald & Co.